PressApril 14, 2023 atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
PressApril 11, 2023 Numinus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion
PressApril 11, 2023 Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
PressApril 11, 2023 COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference
PressApril 11, 2023 Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
PressApril 7, 2023 MAPS PBC Announces Positive Topline Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for Treatment of PTSD
PressApril 4, 2023 Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
PressApril 4, 2023 First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health
PressApril 4, 2023 Psyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note
PressApril 3, 2023 Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
